Millie
your market intelligence analyst
Search Results
16 results
Your search is now limited to «Takeda» expert search.
Business Wire 10/22/2019 14:15
OSAKA, Japon & CHICAGO--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") et COUR Pharmaceutical Development Company, Inc. ("COUR") ont annoncé aujourd'hui que Takeda a obtenu une licence mondiale exclusive pour développer et commercialiser le médicament expérimental CNP-101/TAK-101, une nanoparticule modifiant la réponse immunitaire contenant des gliadines.
Business Wire 10/22/2019 13:27
OSAKA, Japan & CHICAGO--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") en COUR Pharmaceutical Development Company, Inc. ("COUR") hebben vandaag aangekondigd dat Takeda een exclusieve wereldwijde licentie voor het ontwikkelen en commercialiseren van het onderzoeksgeneesmiddel CNP-101/TAK-101, een immuunmodificerend nanodeeltje dat gliadine-eiwitten bevat.
Business Wire 10/22/2019 13:20
OSAKA (Japan) und CHICAGO--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda") und COUR Pharmaceutical Development Company, Inc. („COUR") gaben heute bekannt, dass Takeda eine exklusive globale Lizenz zur Entwicklung und Vermarktung des Prüfpräparats CNP-101/TAK-101 erworben hat, einen immunmodifizierenden Nanopartikel mit dem Protein Gliadin.
Business Wire 10/22/2019 11:36
OSAKA, Japão e CHICAGO--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") e a COUR Pharmaceutical Development Company, Inc. ("COUR") anunciaram hoje que a Takeda adquiriu uma licença global exclusiva para desenvolver e comercializar o medicamento sob investigação CNP-101/TAK-101, uma nanopartícula de modificação da resposta imune contendo proteínas gliadinas.
Business Wire 10/22/2019 09:29
OSAKA, Japón y CHICAGO--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) («Takeda») y COUR Pharmaceutical Development Company, Inc. («COUR») acaban de anunciar que Takeda ha adquirido una licencia global exclusiva para desarrollar y comercializar el fármaco en investigación CNP-101/TAK-101, una nanopartícula que modifica el sistema inmunitario que contiene gliadina.
Business Wire 10/22/2019 06:28
OSAKA, Giappone, e CHICAGO--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") e COUR Pharmaceutical Development Company, Inc. ("COUR") oggi hanno annunciato che Takeda ha acquisito una licenza globale esclusiva per lo sviluppo e la commercializzazione del farmaco sperimentale CNP-101/TAK-101, una nanoparticella contenente proteine della gliadina che modifica il sistema immunitario.

Health Care

Health and Wellness

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Insurance

Information Technologies

Job Titles

Legal and Regulatory

Political Entities

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications